logo
The Legacy of ‘Scavengers Reign' Lives on Through Video Games

The Legacy of ‘Scavengers Reign' Lives on Through Video Games

Gizmodo31-07-2025
It's been little over a year since Scavengers Reign was canceled. Co-created by animator-producers Joseph Bennett and Charles Huettner, Scavengers Reign garnered a modest yet passionate fanbase and went on to earn an Emmy nomination for Outstanding Animated Program. Despite this, however, HBO Max—and by extension Warner Bros. Discovery, HBO Max's parent company—chose not to renew the show for a second season, effectively canceling the series.
Set in the distant future, the animated sci-fi drama followed the survivors of the Demeter 227, a damaged interstellar cargo ship stranded on Vesta, an uncharted alien world thriving with an mesmerizing ecosystem of exotic flora, sentient fauna, and symbiotically entwined wildlife. In order to rescue the remaining crewmembers preserved in cryostasis, the survivors must learn to navigate and ultimately live in communion with their strange new surroundings if they're to have any chance to survive.
Although short-lived, Scavengers Reign undeniably tapped into something deep and resonant among audiences and critics who embraced it. If decay is extant form of life, as the oft-quoted Tumblr meme goes, than Scavengers Reign's legacy nevertheless lives on in spite of its premature cancellation, spreading seeds in the wake of its apparent demise that have begun to yield unexpected fruit in the adjacent medium of video games.
'I think our whole team at this point has seen Scavengers Reign,' Brian Ostrander told io9. A designer and programmer who co-founded the San Francisco-based studio Manzanita Interactive, Ostrander is one of the creative leads behind Dandelion Void, an open-world survival horror sim set aboard the Pergola, a derelict generation ship drifting aimlessly through outer space. Players assume the role of a descendant of the ship's crew who must find a way live among the semi-sentient plant life that has overtaken the Pergola's interior.
While the game formally began production in April of 2023, shortly after Ostrander had been laid off from his full-time game development job, the roots of Dandelion Void go as far back as 2020, when he first read Brian Aldiss' novel Non-Stop, which chronicles follows the struggles of a crew of survivors aboard a generation ship who've descended into tribalism amid an alien infestation. Ostrander cites several other major points of inspiration behind the game's premise and mechanics, including Luigi Serafini's Codex Seraphinianus; Ursula K. Le Guin's novella Paradises Lost; Kim Stanley Robinson's Aurora and Mars trilogy; and Harald Stümpke's The Snouters, widely regarded as the grandfather of all speculative evolution books. Buried in the heart of that teeming thicket of influences lies Scavengers Reign, dead but still dreaming.
'We took a lot of interest in the world of Scavengers Reign, mostly because it feels like the most original portrayal of a fictional ecosystem,' Ostrander says. 'A lot of times, when I'm reading science fiction about an alien world, I find that they really just focus on like one or two creatures, and it's not always apparent how they fit into the world they live in. It's almost like medieval dragons; like, what is the medieval dragon's purpose in the ecosystem? You know, medieval writers didn't concern themselves with that, because that's not the angle they're coming from. That's fine, and a lot of sci-fi authors do that too, but Scavengers Reign, it's like each episode has this new, unique creature that makes sense in the biome it's living in. And you don't see that a lot in sci-fi, and I just can't imagine how much work it was to come up with so many original characters or creature designs.'
Scavenger Reign's influence can be seen and felt through yet another piece of interactive media: the latest expansion for Destiny 2, which was released on consoles and PC earlier this month. Set in an heretofore unexplored region of the universe, Destiny 2: The Edge of Fate takes players both new and old to Kepler, a planetoid suspended in the orbit of a black hole on the rim of Earth's solar system. After receiving an 'invitation' from a cohort of fourth-dimensional beings known as 'the Nine,' players must traverse Kepler in order to unearth its many secrets as they infer the significance of the Nine and their grand cosmic designs.
'We started development almost a year ago,' Alison Lührs, narrative director for Destiny 2, told io9. 'We began in June of last year, and when Robbie [Stevens, assistant game director] and I talked about what our goals were and what we really wanted to do, at least narratively, we wanted to wake our fans up. Something we thought about a lot is how do we get the speculation engine going again of what is the mystery inside of Destiny. And so we had this goal of: how do we have The Edge of Fate kick off the saga, but ultimately pose more questions than it answers, because we want the mystery to be back in Destiny.'
In crafting the alien yet familiar terrain of Kepler, with its amethyst dunescapes dotted with the detritus of crashed colony ships overgrown with extraterrestrial fungi, the team at Bungie pulled inspiration from a host of influences, among them games like Metroid 2 and Castlevania: Symphony of the Night, but also non-game influences including progressive rock, psychedelic jazz, the paintings of Mark Rothko, and the 'New Weird' subgenre of literature, film, and television. During the early pre-production phase of The Edge of Fate, Scavengers Reign popped up on Bungie's radar and left a lasting impression on the team.
'When we were looking at referential material, Scavengers Reign had probably come out, I don't know, like six months before we really got like, knees deep really into the creative process of The Edge of Fate,' Stevens told io9. 'We were staring at that and going like, 'Oh my gosh, the visual design of this world and these stories is so compelling,' especially with how the characters interact with this strange world and how some literally fuse themselves with these environments.'
It was this aspect of Scavengers Reign, the symbiosis between organic and inorganic matter, that inspired Matterspark, a new ability in The Edge of Fate that allows players to fuse with dark matter, transforming themselves into a spherical bundle of thrumming energy. Apart from this, however, it was ultimately another aspect of the show that struck home for Bungie while creating The Edge of Fate.
'[One of the things] that Scavengers Reign really triumphs at is the world building itself, creating a place that is so alien and also inviting at the same time, while also finding the places where the human body intersects with the strange environment around them,' Lührs says. 'Obviously, that was a big influence on us. But, more importantly, is the sense of humanity and the connection of the characters themselves, making sure that no matter how wackadoodle this planet gets, that they still had really, really grounded character work inside of it, so that the audience gets to come along on the journey instead of feeling alienated by it. That was something that we held as a principle as we were working on The Edge of Fate.'
During our interview Stevens mentioned that, prior to going heads-down in the final stretch of The Edge of Fate's production, he had been reading Andy Weir's Project Hail Mary, as well as This Is How You Lose the Time War by Amal El-Mohtar and Max Gladstone.
'It really takes you on a journey that, by the time you get to the end, it feels like you get so much out of it by the end of it.' Stevens told io9. 'I'm getting emotional right now, because of the thing about those characters and the relationship they form with each other.' By a stroke of kismet, the third and final developer I spoke to about Scavengers Reign's lasting influence also cited El-Mothar and Gladstone's novel at the top of their recent reading list.
'In the book club we're doing on our Discord, we're doing This Is How You Lose the Time War,' Joel Burgess, co-founder and head of Soft Rains, told io9. 'I read it like, half of a year ago and then, just like, fell off. So it's been a good excuse for me to go back and dive in so I can finish it this time.' Based in Toronto, the studio—named after Sara Teasdale's 1918 poem 'There Will Come Soft Rains,' which inspired Ray Bradbury's 1950 short story of the same name—has been working on their debut title, Ambrosia Sky, as early as 2022.
Set in the 23rd century, the game centers on Dalia, a deep space disaster specialist working on behalf of the 'Scarabs,' a clandestine sect of field scientists pursuing a 'cure' for death, colloquially referred to as the 'Ambrosia' project. After an unknown disaster strikes an agricultural colony in the rings of Saturn, Dalia—a former inhabitant of the colony—is dispatched to investigate, exhume the remains of the dead, and retrieve anomalous biological samples for future study.
'In the early days of Ambrosia Sky, we thought a lot about, if we do have this agricultural setting, what type of characters and what type of character interactions are really interesting here,' Ambrosia Sky narrative director Kaitlin Tremblay told io9. 'I didn't want to go like, 'She's a farmer in a farm colony.' Like, what's a different perspective, and this is how we got to our sci-fi job of a death cleaner. Scarabs are the sci-fi blend of real world death cleaners, or bio cleaners; people who come in to clean up spaces after people have died. We wanted to blend that with a little bit of the mythological and fantastical sci-fi that we have, and so we gave them this greater creed about pursuing immortality. And this is why they go around the cosmos looking at death and understanding death in order to try to understand how our bodies react to the environmental factors that we find in the cosmos.'
Ambrosia Sky's influences are as eclectic as its gameplay, with Tremblay citing the works of Andy Weir, Beck Chambers, and Jeff VanderMeer as prominent inspirations behind the game's initial premise, characters, and tone, as well as anti-aging research like Nicklas Brendborg's Jellyfish Age Backwards. 'Annihilation was such a big thing for us in the way it looks at the kind of symbiosis between humanity and our ecosystems, and the ways those things can influence each other,' Tremblay says. 'And then combining that with the kind of really character-forward, quiet coziness of Becky Chambers' work that's really introspective and that really kind of digs down deep into these everyday feelings that you have in these great lush settings. So it was really kind of combining a lot of those types of influences along with a lot of my own past work or other things that I'm deeply interested in.'
In addition, Burgess also cited Grim Wilkins' Prophet reboot for Image Comics, along with Robert MacFarlane's 2019 non-fiction book Underland: A Deep Time Journey.
'Mushrooms are having a bit of a moment in the discourse,' Burgess says. 'Mushrooms, fungi, mycelium, et cetera. They're just like a bit more of a household topic now, and I think it's tied up in stuff like, y'know, alternative food and clothing sources. Mycelium is fascinating in general. But then when we start thinking about death, death and space, and what would that mean; How would you deal with it, what kind of character would [interact with death in space regularly]? There's just like this harmony of how we think about decay and rot and mushrooms and fungi, and like, the ick factor of all that. But also, that's such an important and sort of cryptic, hard to understand part of life on our own planet.'
While Ambrosia Sky was already well into production before Scavengers Reign first premiere, the show's aesthetic, premise, and themes still emboldened Soft Rain's belief that it had tapped into something that was real and resonant within the zeitgeist. 'We love Scavengers Reign,' Tremblay says. 'I adore that show. I think it's brilliant, and I think it does a lot of really interesting things like, creature ecosystem and worldbuilding. One thing for me, and this already existed for us [with Ambrosia Sky], so I think it was more a validation that we were hitting on an idea that other people were interested in and there was ground there, was the way they made a lot of their grotesque stuff really beautiful. Like, there's a lot of really gross, gory deaths in Scavengers Reign that are actually quite aesthetically appealing and mesmerizing. And I think that was something that kind of sat next to what we were doing with Ambrosia Sky as well. The idea wasn't new from Scavengers Reign to us, but it was affirming and validating.'
'I think Scavengers Reign really, really nails something a lot of sci-fi takes for granted, [in that] it's alien in a way that feels, with time, it would be understandable.' Burgess told io9. 'Like, there is a cohesion that gives credibility to what I'm seeing as completely alien. It doesn't make sense, but if I lived here long enough and I studied it hard enough, it might make sense. And they show that in the run of the story as well, like you can understand it, right? Sort of the, you know, the corollary and fantasy of, you know, like magic has to follow rules if you're writing a fantasy thing, right? It feels like that's something that's something a Scavengers Reign gets right in a big way.'
Since news of Scavengers Reign's cancellation first broke, the future of the series has been in a state of suspended animation, pun half-intended. Co-creator Joseph Bennett took to Instagram last November to announce that Netflix had passed on greenlighting a second season following the series' arrival on the streaming service, in addition to sharing a teaser trailer for what a second season would look like.
'This is not the end,' Bennett wrote. 'There is more story to be told, we are ready to make another season, and we produced in-house at Green Street a teaser for what was going to come in the second season.' While the future of Scavengers Reign remains in flux, its legacy nonetheless endures through the imaginations and artwork of audiences and artists alike. Big things have small beginnings, and while decay and deterioration might be an inexorable fact of the universe, there's still nothing quite so powerful as an idea whose time has finally come.
Want more io9 news? Check out when to expect the latest Marvel, Star Wars, and Star Trek releases, what's next for the DC Universe on film and TV, and everything you need to know about the future of Doctor Who.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ESPN, Fox team up for bundled streaming service in October
ESPN, Fox team up for bundled streaming service in October

Yahoo

time11 minutes ago

  • Yahoo

ESPN, Fox team up for bundled streaming service in October

Aug. 11 (UPI) -- Disney's ESPN and Fox Corp. on Monday announced the two rivals are joining forces to offer a streaming service to consumers as a bundle for $39 per month. The two media giants announced the service but last week ESPN and Fox each announced separate all-in-one streaming apps. The services can be downloaded on devices, including cellphones and tablets, and can be accessed on smart TVs and gaming consoles. With viewership declining on TV, including cable, media companies have turned to streaming services as a way to boost viewership and revenue. CNBC reported that sports is a way to accomplish this. Last week, both companies announced their services -- ESPN's Direct to Consumer Unlimited Offering and Fox One -- will launch on Aug. 21 before the college football and NFL seasons. But the bundle won't be available until October. ESPN's separate service will cost $29.99 month and Fox's will be $19.99. Also, ESPN will offer a bundle with Disney's other streaming services, Disney+ and Hulu, for $35.99 per month. Besides events, both companies present sports news. The ESPN service will include live sports and programming from its TV networks, including ESPN2, the SEC Network, the ACC Network, as well as Disney-owned ABC. ESPN also reached an agreement last week with the NFL to acquire the NFL Network, including the Red Zone. And ESPN last week signed a deal with the WWW for U.S. rights in 2026 to its biggest wrestling events, including WrestleMania, the Royal Rumble and SummerSlam. In all, ESPN/ABC cover 47,000 live events each year, as well as studio shows and original programming. ESPN and ABC sports include Monday Night Football, college football and basketball, NHL, NBA, Major League Soccer, golf, tennis and motorsports. In addition, an enhanced app will integrate game statistics, betting information, fantasy sports, multi-view options and a "personalize SportsCenter For You," the company said. Fox's parent company offers Tubi and Fox Nation. Fox's sports networks include FS1, FS2 and the Big Ten Network. The company said Fox One won't have original content. Last week, Fox CEO Lachlan Murdoch and Disney CEO Bob Iger said during earnings calls that they were considering offering bundle services. Fox Sports' coverage includes NFL, college football and basketball, Major League Baseball, FIFA World Cup, Major League Soccer, motorsports, WNBA, LIV Golf and boxing. Three other media companies offer sports: Comcast's NBC, Warner Bros. Discovery's TNT and Paramount Skydance's CBS. NBC, which has the rights to the Olympics, has Peacock streaming, and CBS offers Paramount+, services that include sports. TNT doesn't have a specific app but its services can be bundles with other apps. On Monday, Paramount announced plans to televise UFC events starting next year.

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Yahoo

time11 minutes ago

  • Yahoo

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval path for Sanfilippo syndrome Type A aligned with FDA; Phase 1/2 study nearing completion of enrollment; planning underway for a global Phase 3 confirmatory study On track to submit regulatory applications in 2025 to begin clinical testing of one to two additional TransportVehicleTM (TV)-enabled programs Preclinical research on ATV:Abeta program for Alzheimer's disease published in the journal Science SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the second quarter ended June 30, 2025, and provided business highlights. 'The FDA's priority review of our BLA for tividenofusp alfa and alignment on an accelerated approval path for DNL126 are key milestones highlighting the potential of our Transport Vehicle (TV) platform to catalyze a new class of blood-brain barrier-crossing therapeutics,' said Ryan Watts, Ph.D., CEO of Denali Therapeutics. 'With launch readiness in motion and a growing portfolio of TV-enabled enzyme, antibody, and oligonucleotide programs, Denali is poised to deliver meaningful treatments for people living with lysosomal, neurodegenerative, and other serious diseases.' Second Quarter 2025 and Recent Program Updates CLINICAL PROGRAMS Tividenofusp alfa (DNL310, ETV:IDS) for Hunter syndrome (MPS II) In July 2025, Denali announced that the U.S. Food and Drug Administration (FDA) accepted its Biologics License Application (BLA) for tividenofusp alfa for priority review, assigning a Prescription Drug User Fee Act (PDUFA) target action date of January 5, 2026. The BLA seeks accelerated approval based on a data package including results from the Phase 1/2 study in individuals with Hunter syndrome. Tividenofusp alfa is an investigational, next-generation enzyme replacement therapy designed to cross the blood-brain barrier (BBB) and deliver the iduronate-2-sulfatase (IDS) enzyme throughout the body and brain. The FDA previously granted tividenofusp alfa Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations. Denali continues to prepare for commercial launch and is conducting the Phase 2/3 COMPASS study to support global regulatory submissions. DNL126 (ETV:SGSH) for Sanfilippo syndrome type A (MPS IIIA) Today, Denali announced that it has reached alignment with the FDA's Center for Drug Evaluation and Research (CDER) that cerebrospinal fluid heparan sulfate (CSF HS) may be considered a reasonably likely surrogate endpoint to predict clinical benefit and may therefore be used to support accelerated approval of DNL126 for MPS IIIA. Additional 49-week data from the ongoing open-label Phase 1/2 study are consistent with previously announced 25-week data, demonstrating a significant reduction in CSF HS from baseline, including normalization, and a safety profile that supports continued development. Enrollment in the Phase 1/2 study is nearly complete, and planning is underway for a confirmatory global Phase 3 study. TAK-594/DNL593 (PTV:PGRN) for GRN-related frontotemporal dementia Denali and Takeda continue their collaboration to develop DNL593, an investigational therapeutic designed to deliver progranulin across the BBB for the treatment of granulin (GRN) mutation-associated frontotemporal dementia (FTD-GRN). A Phase 1/2 study is ongoing. BIIB122/DNL151 (small molecule LRRK2 inhibitor) for the treatment of Parkinson's disease (PD) Denali and Biogen are co-developing LRRK2 inhibitors for Parkinson's disease. In May 2025, Biogen announced that the Phase 2b LUMA study of BIIB122 completed enrollment, with a readout expected in 2026. Denali is also conducting the Phase 2a BEACON study focused on LRRK2-associated PD. IND-ENABLING STAGE PROGRAMS Denali expects to submit regulatory applications to begin clinical testing of one to two TV-enabled programs each year over the next three years across its Enzyme TV (ETV), Antibody TV (ATV), and Oligonucleotide TV (OTV) franchises. The most advanced programs include: DNL952 (ETV:GAA) for Pompe disease; DNL111 (ETV:GCase) for Parkinson's/Gaucher disease; DNL622 (ETV:IDUA) for MPS I; DNL921 (ATV:Abeta) for Alzheimer's disease; DNL628 (OTV:MAPT) for Alzheimer's disease; and DNL422 (OTV:SNCA) for Parkinson's disease. Denali announced publication of preclinical data on ATV:Abeta in the August 7, 2025, issue of the journal Science. The research demonstrated that delivering an anti-amyloid beta antibody across the BBB using Denali's TV platform improved brain distribution and reduced the risk of amyloid-related imaging abnormality (ARIA) in a mouse model of Alzheimer's disease, compared to conventional antibody treatment. The findings suggest that TV platform-enabled brain delivery of immunotherapy bypasses amyloid-laden large vessels by traveling through smaller capillaries, offering a potential strategy to mitigate ARIA risk seen with first-generation anti-amyloid therapies. The Science article can be accessed here. Participation in Upcoming Investor Conferences Cantor Global Healthcare Conference 2025, September 3 - 5 (New York City) Morgan Stanley 23rd Annual Global Healthcare Conference, September 8 - 10 (New York City) Baird 2025 Global Healthcare Conference, September 9 - 10 (New York City) H.C. Wainwright 27th Annual Global Investment Conference, September 8 - 10 (New York City) Deutsche Bank BioPharm Corporate Day, September 18 - 19 (Austria) Stifel 2025 Healthcare Conference, November 11 - 13 (New York City) Jefferies Global Healthcare Conference, November 17 - 20 (London) Second Quarter 2025 Financial Results Net loss was $124.1 million for the quarter ended June 30, 2025, compared to net loss of $99.0 million for the quarter ended June 30, 2024. Total research and development expenses were $102.7 million for the quarter ended June 30, 2025, compared to $91.4 million for the quarter ended June 30, 2024. The increase of approximately $11.3 million was attributable to an increase of $7.3 million in TV program external research and development expenses, primarily driven by increased spend on multiple preclinical programs, and increases of $7.6 million and $6.2 million in other research and development expenses and personnel-related expenses, respectively, both driven by the commencement of operations at Denali's large molecule manufacturing facility in Salt Lake City, Utah. These increases were partially offset by a $9.8 million decrease in small molecule programs, primarily due to the winding down of activities related to the Phase 2/3 HEALEY ALS Platform Trial. General and administrative expenses were $32.3 million for the quarter ended June 30, 2025, compared to $25.2 million for the quarter ended June 30, 2024. The increase of $7.1 million was primarily driven by activities related to preparations for a potential commercial launch for tividenofusp alfa. Cash, cash equivalents, and marketable securities were approximately $977.4 million as of June 30, 2025. About Denali Therapeutics Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB, and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco. For additional information, please visit Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali's TV platform and its therapeutics and commercial potential; statements made by Denali's Chief Executive Officer; plans, timelines, and expectations relating to DNL310, including the PDUFA target action date and the timing, likelihood of, and scope of regulatory approval, the ongoing global Phase 2/3 COMPASS study and the likelihood of global approvals, and planned commercial launch; plans, timelines, and expectations related to DNL126, including enrollment in the ongoing Phase 1/2 study, plans regarding the confirmatory global Phase 3 study, planned engagement with the FDA, and the likelihood and scope of regulatory approvals; plans regarding DNL593 and the ongoing Phase 1/2 study; plans, timelines, and expectations regarding DNL151, including with respect to the ongoing Phase 2b LUMA study and the timing and likelihood of readout, and the ongoing Phase 2a BEACON study; plans and expectations for Denali's preclinical programs, including the timing of advancement to clinical studies; the findings from Denali's recent Science publication and their therapeutic potential regarding ARIA risk; Denali's participation in upcoming investor conferences; and Denali's future operating expenses and anticipated cash runway. All drugs currently being developed by Denali are investigational and have not received regulatory approval for any indication. Actual results are subject to risks and uncertainties and may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to, risks related to: the impact of adverse economic conditions, tariffs, and inflation on Denali's business and operations; the occurrence of any event, change, or other circumstance that could give rise to the termination of Denali's agreements with Sanofi, Takeda, Biogen, or other collaborators; Denali's transition to a late-stage clinical drug development company; Denali's and its collaborators' ability to complete the development and, if approved, commercialization of its product candidates; Denali's and its collaborators' ability to enroll patients in its ongoing and future clinical trials; Denali's reliance on third parties for the manufacture and supply of its product candidates for clinical trials; Denali's dependence on successful development of its blood-brain barrier platform technology and its programs and product candidates; Denali's and its collaborators' ability to conduct or complete clinical trials on expected timelines; the risk that preclinical profiles of Denali's product candidates may not translate in clinical trials; the potential for clinical trials to differ from preclinical, early clinical, preliminary or expected results; the risk of significant adverse events, toxicities, or other undesirable side effects; the uncertainty that product candidates will receive regulatory approval necessary to be commercialized; Denali's ability to continue to create a pipeline of product candidates or commercialize products; developments relating to Denali's competitors and its industry, including competing product candidates and therapies; Denali's ability to obtain, maintain, or protect intellectual property rights related to its product candidates; implementation of Denali's strategic plans for its business, product candidates, and blood-brain barrier platform technology; Denali's ability to obtain additional capital to finance its operations, as needed; Denali's ability to accurately forecast future financial results and hedge against financial risk in the current environment; and other risks and uncertainties, including those described in Denali's most recent Annual Report and Quarterly Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) on February 27, 2025 and May 6, 2025, and Denali's future reports to be filed with the SEC. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results, or to make changes in Denali's expectations, except as required by law. Denali Therapeutics Consolidated Statements of Operations(Unaudited)(In thousands, except share and per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 102,696 $ 91,399 218,923 198,415 General and administrative 32,267 25,194 61,620 50,430 Total operating expenses 134,963 116,593 280,543 248,845 Gain from divestiture of small molecule programs — — — 14,537 Loss from operations (134,963 ) (116,593 ) (280,543 ) (234,308 ) Interest and other income, net 10,844 17,567 23,454 33,480 Net loss $ (124,119 ) $ (99,026 ) $ (257,089 ) $ (200,828 ) Net loss per share, basic and diluted $ (0.72 ) $ (0.59 ) $ (1.50 ) $ (1.26 ) Weighted average number of shares outstanding, basic and diluted 171,449,847 168,831,329 171,336,568 159,117,759 Denali Therapeutics Consolidated Balance Sheets(Unaudited)(In thousands) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 141,207 $ 174,960 Short-term marketable securities 757,745 657,371 Prepaid expenses and other current assets 35,754 32,105 Total current assets 934,706 864,436 Long-term marketable securities 78,463 359,373 Property and equipment, net 58,717 55,236 Finance lease right-of-use asset 50,363 47,533 Operating lease right-of-use asset 21,022 22,861 Other non-current assets 22,970 24,741 Total assets $ 1,166,241 $ 1,374,180 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 10,844 $ 11,137 Accrued compensation 12,068 24,728 Accrued clinical and other research & development costs 23,379 22,822 Accrued manufacturing costs 9,028 12,779 Operating lease liability, current 8,871 8,308 Deferred research and development funding liability, current 19,861 14,129 Other accrued costs and current liabilities 7,006 8,305 Total current liabilities 91,057 102,208 Operating lease liability, less current portion 32,110 36,673 Finance lease liability, less current portion 5,577 5,615 Deferred research funding and development liability, less current portion 10,444 — Total liabilities 139,188 144,496 Total stockholders' equity 1,027,053 1,229,684 Total liabilities and stockholders' equity $ 1,166,241 $ 1,374,180 Investor Contact:Laura Hansen, Media Contact:Erin Pattonepatton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Bruce Springsteen biopic to premiere at NY Film Festival
Bruce Springsteen biopic to premiere at NY Film Festival

Yahoo

time11 minutes ago

  • Yahoo

Bruce Springsteen biopic to premiere at NY Film Festival

Bruce Springsteen biopic to premiere at NY Film Festival NEW YORK — Bruce Springsteen will bless New York City with an early look at his upcoming biopic, 'Deliver Me From Nowhere.' The 2025 New York Film Festival announced Monday that the film, starring Jeremy Allen White as the New Jersey rocker, will be its Spotlight Gala selection, premiering Sept. 28 at Lincoln Center's Alice Tully Hall. The Boss is expected to attend the screening, along with director and writer Scott Cooper, and the film's stars, including Jeremy Strong, who plays his manager and record producer Jon Landau, and Odessa Young, who stars as Springsteen's love interest Faye. Officially titled 'Springsteen: Deliver Me From Nowhere,' the 20th Century Studios musical drama centers on the making of Springsteen's sixth album, 'Nebraska,' in 1982. Recorded on a 4-track recorder in his New Jersey bedroom and without The E Street Band, the folksy solo outing — released before the mega-selling 'Born in the U.S.A.' — is ranked among Rolling Stone magazine's 500 Greatest Albums of All Time. Adapted from Warren Zanes' book of the same title, the film also stars Stephen Graham, Paul Walter Hauser and Gaby Hoffmann. New York Film Festival's artistic director Dennis Lim called the movie a 'fitting tribute to a living legend' in Monday's announcement. 'The New York Film Festival has always felt like a spiritual home for the kind of cinema I believe in,' Cooper said in a statement. 'To now arrive with a film about Bruce Springsteen — an artist whose music shaped not just a country but my own sense of storytelling — is something I could never have imagined.' He added, 'Getting to know Bruce, to explore his world and his spirit, has been one of the most profound creative experiences of my life. To share that experience with New York audiences, in a city that defines artistic possibility, is both an honor and a responsibility I hold with deep gratitude.' White, who won two Emmy Awards for his star turn in the Hulu series 'The Bear,' previously portrayed professional wrestler Kerry Von Erich on the big screen in 'The Iron Claw.' But for his latest role, the Brooklyn-born Calvin Klein underwear model endured more pressure for portraying the Rock & Roll Hall of Famer. 'Getting that out, it was so much pressure,' the actor told Jimmy Fallon on 'The Tonight Show' in June. 'You're playing a real person — nevermind Bruce Springsteen — and I was really touched [when] the trailer came out. I had more texts than when I blacked out and won that Golden Globe (for The Bear).' 'I didn't realize trailers were that big of a thing,' he added. 'Springsteen: Deliver Me From Nowhere' is expected to hit theaters Oct. 24. _______

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store